Guillain-Barré Syndrome Following Suspected Zika Virus Infection: A Rare but Important Neurological Manifestation
Keywords:
Guillain-Barré syndrome, Zika virus infection, acute flaccid paralysis, post-infectious neuropathyAbstract
Zika virus infection is typically a mild, self-limited febrile rash illness, but growing evidence suggested potential neurological complications during outbreaks. We report a case of acute flaccid paralysis consistent with Guillain-Barré syndrome (GBS) occurring shortly after a clinically compatible illness suggestive of Zika virus infection in a returning traveler. The patient developed rapidly progressive, symmetrical limb weakness with areflexia, albuminocytologic dissociation in cerebrospinal fluid, and electrophysiological findings supportive of acute inflammatory demyelinating polyneuropathy. He improved after intravenous immunoglobulin and supportive care. This case highlights the importance of recognizing post-infectious neuropathy following suspected Zika virus disease, especially in settings where laboratory confirmation may be limited and serology may be complicated by flavivirus cross-reactivity.
References
1. Duffy MR, Chen TH, Hancock WT, Powers AM, et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med. 2009 Jun 11;360(24):2536-43. DOI: https://doi.org/10.1056/NEJMoa0805715 PMid:19516034
2. Hayes EB. Zika virus outside Africa. Emerg Infect Dis. 2009 Sep;15(9):1347-50. DOI: https://doi.org/10.3201/eid1509.090442 PMid:19788800 PMCid:PMC2819875
3. Cao-Lormeau VM, Roche C, Teissier A, et al. Zika virus, French polynesia, South pacific, 2013. Emerg Infect Dis. 2014 Jun;20(6):1085-6. DOI: https://doi.org/10.3201/eid2006.140138 PMid:24856001 PMCid:PMC4036769
4. Pan American Health Organization / World Health Organization (PAHO/WHO). Neurological syndrome, congenital malformations, and Zika virus infection. Epidemiological alert. 1 Dec 2015. Available from: https://www.paho.org/en/documents/1-december-2015-neurological-syndrome-congenital-malformations-and-zika-virus-infection
5. Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet. 2005 Nov 5;366(9497):1653-66. DOI: https://doi.org/10.1016/S0140-6736(05)67665-9 PMid:16271648
6. van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol. 2008 Oct;7(10):939-50. DOI: https://doi.org/10.1016/S1474-4422(08)70215-1 PMid:18848313
7. Yuki N, Hartung HP. Guillain-Barré syndrome. N Engl J Med. 2012 Jun 14;366(24):2294-304. DOI: https://doi.org/10.1056/NEJMra1114525 PMid:22694000
8. Sejvar JJ, Kohl KS, Gidudu J, Amato A, Bakshi N, et al. Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2011 Jan 10;29(3):599-612. DOI: https://doi.org/10.1016/j.vaccine.2010.06.003 PMid:20600491
9. Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2014 Sep 19;2014(9):CD002063. DOI: https://doi.org/10.1002/14651858.CD002063.pub6 PMid:25238327 PMCid:PMC6781841
10. Cochrane Neuromuscular Group. Intravenous immunoglobulin for Guillain-Barré syndrome (evidence summary). Cochrane. 2014.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2016 sf sdfhgh

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
The authors retain the copyright of their article, with first publication rights granted to Medsci Publications.

